### Cytarabine

**Indication:** Anaplastic large cell lymphoma, ALK-negative

**INN:** Cytarabine

**Medicine type:** Chemical agent

**List type:** Complementary

**Formulations:** Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial

**EML status history:** First added in 2023 (TRS 1049)

**Sex:** All

**Age:** Also recommended for children

**Therapeutic alternatives:** The recommendation is for this specific medicine

**Patent information:** Patents have expired in most jurisdictions

**Read more about patents.**

### Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the current listings of cyclophosphamide, cytarabine, dexamethasone, doxorubicin, etoposide, ifosfamide, methotrexate, prednisolone and vinblastine on the complementary list of the EML and EMLc be extended to include the new indication of anaplastic large cell lymphoma (ALCL). These medicines are recognized as part of the standard of care for ALCL. Their benefits and harms were accepted as being well established from use in other indications in children and in adults. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose form of cytarabine (100 mg/mL in vial) to the EML and EMLc.